Development of a reminiscence therapy online platform with machine learning to increase engagement with people living with dementia and their care partners

开发具有机器学习功能的回忆疗法在线平台，以增加与痴呆症患者及其护理伙伴的互动

• 批准号: 10227234
• 负责人: Lisbeth Sanders
• 金额: $ 110.76万
• 依托单位: LIFEBIO INC
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10227234
• 关键词: Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; American; Artificial Intelligence; Assisted Living Facilities; Behavioral Symptoms; Books; Caregivers; Caring; Cause of Death; Cessation of life; Cognition; Communication; Consumption; Data; Dementia; Dependence; Development; Disease; Elderly; Elements; Empathy; Environment; Evaluation; Event; Exercise Therapy; Family Caregiver; Family member; Feedback; Financial Hardship; Focus Groups; Generations; Health Personnel; Impaired cognition; Individual; Institutes; Internet; Intervention; Interview; Knowledge; Life; Machine Learning; Memory; Mental Health; Modification; Monitor; Moods; Music; Nature; Nursing Homes; Oral; Outcome; Output; Participant; Patients; Persons; Phase; Pilot Projects; Procedures; Process; Qualitative Evaluations; Quality of life; Quantitative Evaluations; Reporting; Research; Residential Treatment; Side; Small Business Innovation Research Grant; Source; Speech; Surveys; Symptoms; System; Techniques; Testing; Text; Time; Training; United States Centers for Medicare and Medicaid Services; Work; acceptability and feasibility; aged; base; caregiving; dementia care; depressive symptoms; design; effective intervention; experience; improved; interactive tool; life history; long term memory; novel; person centered; physical conditioning; point of care; programs; prototype; psychological symptom; symptomatology; tool; usability; user-friendly; web site

PROJECT SUMMARY Almost 6 million Americans are living with Alzheimer’s disease (AD) or AD-related dementias, and the number of affected individuals is rapidly growing. Symptoms include impaired cognition, resulting in difficulty in performing daily activities and consequent functional dependence on others. The progressive nature of AD and ADRD can result in increasing degrees of care required from professional and family caregivers. Non- pharmacologic interventions positively influence cognition, mood, and other behavioral and psychological symptoms of dementia, and one well-established intervention, life story work (the use of written and oral life histories), serves as an effective technique that can elicit conversation and memories in those with AD and ADRD. However, generating useful life story materials is a time-consuming task for caregivers. To overcome this barrier, LifeBio Inc. is developing a reminiscence therapy platform —LifeBio MemoryTM— with a novel machine-learning-based application that converts speech to text and generates life stories to serve as an interactive tool to cultivate communication between people living with dementia and their family and caregivers. The LifeBio MemoryTM platform application will elicit and store individuals’ stories, photos, and videos and ultimately deliver personalized, point-of-care reminiscence therapy exercises for patients. In preliminary work supporting this Direct-to-Phase II proposal, LifeBio Inc. partnered with the Benjamin Rose Institute on Aging to conduct a pilot study in nursing homes, which showed a significant decrease in depressive symptoms among participants in LifeBio Inc.’s intervention and revealed that the majority of participants considered knowledge of their life story to be important for caregivers, while caregivers also reported positive experiences in relation to the impact of the intervention on caregiving. In this project we will: 1) Develop prototype enhancements of the existing LifeBio program and conduct focus group evaluations of these prototypes with 12 existing or former LifeBio users, 20 dementia care professionals familiar with LifeBio and 6 older adults with early-stage dementia to help maintain person-centered practices throughout the research process; 2) Finalize the LifeBio Memory product, which will include the development of a system to automatically record and process individuals’ life stories. 3) Conduct a full-scale fidelity trial of the complete package with 40 care professionals and 160 dementia care dyads across within an assisted living setting. The product of this Direct-to-Phase II proposal, LifeBio Memory™, will be a novel, scalable, and easily implemented solution through which caregivers and healthcare providers can offer person-centered care to people living with AD and AD-related dementias.

项目摘要 近600万美国人患有阿尔茨海默病（AD）或AD相关痴呆症， 受影响的人正在迅速增加。症状包括认知受损，导致难以 进行日常活动，并因此对他人产生功能依赖。AD的进步性和 ADRD可能导致需要专业和家庭护理人员提供的护理程度增加。非 药物干预积极影响认知、情绪和其他行为和心理 痴呆症的症状，以及一个行之有效的干预措施，生活故事工作（使用书面和口头生活 历史），作为一种有效的技术，可以引发AD患者的对话和记忆， ADRD。然而，生成有用的生活故事材料对护理人员来说是一项耗时的任务。克服 这个屏障，生命生物公司，正在开发一个回忆治疗平台-LifeBio MemoryTM- 基于机器学习的应用程序，可将语音转换为文本，并生成生活故事， 互动工具，以培养痴呆症患者及其家人和照顾者之间的沟通。 LifeBio MemoryTM平台应用程序将收集和存储个人的故事、照片和视频， 最终为患者提供个性化的即时回忆治疗练习。在初步工作中 支持这一直接到第二阶段的建议，生命生物公司。与本杰明·罗斯老龄化研究所合作， 在养老院进行了一项试点研究，结果显示， LifeBio Inc.的参与者的干预，并显示，大多数参与者认为知识， 他们的生活故事对照顾者很重要，而照顾者也报告了与以下方面有关的积极经历： 干预对生育的影响。在这个项目中，我们将：1）开发原型增强的 现有的LifeBio计划，并对这些原型进行焦点小组评估， LifeBio用户、20名熟悉LifeBio的痴呆症护理专业人员和6名患有早期痴呆症的老年人 帮助在整个研究过程中保持以人为本的做法; 2）完成生命生物记忆 该产品将包括开发一个自动记录和处理个人生活的系统 故事. 3)对40名护理专业人员和160名痴呆症患者进行全面的保真度试验 在一个辅助生活环境中照顾二人组。该产品的直接到第二阶段的建议，生命生物 Memory™将是一种新颖、可扩展且易于实施的解决方案， 提供者可以为AD和AD相关痴呆患者提供以人为本的护理。